gestodene + ethinyl estradiol (Assiut University)

Gestodene + ethinyl estradiol is a combined oral contraceptive (COC) formulation consisting of a synthetic progestin (gestodene) and a synthetic estrogen (ethinyl estradiol). In a Phase 4 clinical trial conducted by Assiut University (NCT03890042), this specific COC was evaluated for the treatment of symptomatic adenomyosis. The therapeutic effect in adenomyosis is achieved by inducing endometrial atrophy and decreasing the production of endometrial prostaglandins, which leads to a reduction in menstrual blood loss (menorrhagia) and a decrease in pelvic pain (dysmenorrhea). While the trial found that both this COC and dienogest were effective in managing symptoms over a six-month period, dienogest showed superior efficacy in pain reduction, whereas the COC formulation was associated with fewer side effects and improvements in uterine artery blood flow and uterine volume.

Brand names

GyneraMinuletFemodeneMelianeLogynonMirelle

Other names

gestodene-ethinyl estradiolCOCcombined oral contraceptive